SIGA Technologies, Inc.
NASDAQ:SIGADrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $201.19M
- Beta
- 0.85
- P/E (TTM)
- 15.2
- EPS (TTM)
- $0.28
- Dividend yield
- 13.97%
Volume 0.37M
Average 0.61M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
SIGA Technologies, Inc.
NASDAQ:SIGA
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -10.5% | +79.2% (2yr)1 analysts |
| Revenue | N/A | N/A | -5.1% | +29.2% (2yr)1 analysts |
| Net Income | N/A | N/A | -11.8% | +80.5% (2yr)1 analysts |
| EBIT | N/A | N/A | -17.8% | +103.5% (2yr)1 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.1% over three years. Forward estimates point to EBIT at +103.5% (2yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $837.18M | $44.46 | Undervalued | 1.7 | +2.04% |
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $662.30M | $7.56 | Not rated | -5.1 | -63.66% |
Esperion Therapeutics, Inc. NASDAQ:ESPR | $661.15M | $3.18 | Undervalued | -107.3 | +13.98% |
Aquestive Therapeutics, Inc. NASDAQ:AQST | $491.44M | $3.91 | Not rated | -8.3 | -35.16% |
CytomX Therapeutics, Inc. NASDAQ:CTMX | $444.73M | $2.04 | Not rated | -8.8 | -48.21% |
SNDL Inc. NASDAQ:SNDL | $335.34M | $1.37 | Undervalued | -47.4 | -17.28% |
Emergent BioSolutions Inc. NYSE:EBS | $297.69M | $5.79 | Fairly Valued | -47.9 | -44.39% |
Organogenesis Holdings Inc. NASDAQ:ORGO | $105.15M | $0.81 | Overvalued | -1086.7 | -83.37% |
DarioHealth Corp. NASDAQ:DRIO | $12.35M | $1.26 | Not rated | 5.5 | -63.36% |
Continue the stock analysis
Jump to another research area for this company.